Salute e Benessere

Cell Culture Market Worth $57.9 billion | MarketsandMarkets™

Browse in-depth TOC on "Cell Culture Market"997 - Tables54 - Figures772 - Pages Browse in-depth TOC on "Cell Culture Market" 997 - Tables 54 - Figures 772 - Pages Cell Culture Market Scope: The consumables segment accounted for the largest share of the product segment in the cell culture market in 2023. Based on products, the cell culture market is segmented into consumables and equipment. Consumables are further segmented into sera, media, reagents; vessels; and...
PR Newswire
26/03/2024

Marine Collagen Market Embraces New Frontiers: New Animal-Free Options Emerge |…

Key Coverage in the Marine Collagen Market Report Key Coverage in the Marine Collagen Market Report Download the Sample PDF report to explore key market insights and trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-11528 Demand for marine collagen -based nutricosmetics is being driven by the confluence of health and beauty trends. The supposed advantages for skin elasticity, hydration, and anti-aging properties are driving sales of marine collagen and...
PR Newswire
26/03/2024

New White Paper Calls for 'Value' Re-think in Orthopedic Healthcare

Titled 'The Value Paradox: the hidden cost of faulty funding in orthopedics', the white paper, published by Toby Orthopaedics, argues that a skewed vision of value is leaving surgeons without the necessary tools to operate to the best of their abilities - with significant knock-on effects to patient care, surgeon well-being, and the broader economy. Titled' The Value Paradox: the hidden cost of faulty funding in orthopedics' , the white paper, published by Toby Orthopaedics, argues that a...
PR Newswire
26/03/2024

Avicenna.AI secures FDA clearance for two healthcare AI solutions

Addressing the serious issue of delayed and missed findings in diagnostic imaging, CINA-iPE is an AI-powered tool that detects incidental pulmonary embolism during routine CT scans. Unsuspected pulmonary embolism is a common finding in routine CT scans of the chest, but as little as 25% of emboli are reported during the initial interpretation. This is particularly relevant in the cancer patient population, where pulmonary embolism is a significant cause of mortality. Addressing the serious...
PR Newswire
26/03/2024

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on…

AIM ImmunoTech Inc.(NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host aconference call and webcastto discuss the Company's Q4/FY2023 operational and financial results on Tuesday, April 2, 2024, at 8:30 AM ET. The call will be hosted by members of AIM's leadership team, Chief Executive Officer Thomas K. Equels and Scientific Officer Christopher McAleer, PhD. Interested participants and investors may access the conference call by dialing (877)...
Nasdaq GlobeNewswire
26/03/2024

One2Treat launches groundbreaking treatment-decision approach to clinical…

In today's clinical studies, the focus on one or two primary endpoints often leads to underutilization of valuable data and fails to capture the holistic impact of treatments on patients. Moreover, if the primary endpoints are not met, the trial is considered "negative" regardless of any treatment benefits on other endpoints. Even when a trial is successful, many of the potential insights may be ignored. More importantly, the primary endpoints often fail to reflect what matters to…
PR Newswire
26/03/2024

Essential Pharma and AcedrA Biopharmaceuticals sign Distribution Agreement to…

Essential Pharma specializes in ensuring sustainable access to clinically differentiated, low-volume, and difficult-to-manufacture medicines for chronic diseases and acute care. As a global leader in acquiring, integrating, and maintaining Essential medicines at risk of shortages or discontinuation, Essential Pharma works collaboratively with partners worldwide to uphold the highest standards of pharmaceutical manufacturing. Emma Johnson, CEO of Essential Pharma, commented : “As we...
Nasdaq GlobeNewswire
26/03/2024

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

The combination medication is used to relieve the signs and symptoms of rheumatoid arthritis and osteoarthritis while decreasing the risk of developing ulcers of the stomach and upper intestines people may experience from ibuprofen alone. The combination medication is used to relieve the signs and symptoms of rheumatoid arthritis and osteoarthritis while decreasing the risk of developing ulcers of the stomach and upper intestines people may experience from ibuprofen alone. According to IQVIA...
PR Newswire
26/03/2024

Electrolux Group Sustainability Report 2023: High global warming gases phased…

"Our sustainability performance in 2023 and our new science-based climate target approved in 2024 show that together we continue to build a better company, create better solutions and enable better living," says Elena Breda, Chief Technology & Sustainability Officer at Electrolux Group. "This highlights the power of our combined people, planet and business perspectives," Breda adds. "Our sustainability performance in 2023 and our new science-based climate target…
PR Newswire
26/03/2024

Nanoscope Therapeutics Announces Positive Top-line Results from Randomized…

Improvements in visual function persisted or increased following week 52 in the study, demonstrating the durable effect of a single intravitreal injection of MCO-010. BCVA improvement at week 76, a key secondary endpoint, was statistically significant in the high-dose treatment group compared to the control group (0.539 LogMAR; p=0.001). At week 76, the improvement in BCVA in the low-dose treatment group was not statistically significant compared to control (0.374 LogMAR; p=0.065). These results…
PR Newswire
26/03/2024

Digital Diagnostics Market to reach over USD 6.32 Bn by the year 2031 -…

Digital Diagnostics Market Report Scope: Digital Diagnostics Market Report Scope: Request for Sample Pages:https://www.insightaceanalytic.com/request-sample/2372 Digital technologies are applied to healthcare diagnostics to change the way diseases are identified, tracked, and treated. This process is known as digital diagnostics. Digital diagnostics offer a more accurate and practical approach to healthcare diagnostics, lowering mistakes, improving accuracy, and enabling early...
PR Newswire
26/03/2024

Research published in Journal of the American Chemical Society highlights…

Curve Therapeutics is a leader in the discovery of innovative therapeutics to address disease targets which are difficult to target using conventional drug discovery methods. Through the utilisation of its world leading Microcyle® discovery platform, Curve can screen directly inside mammalian cells, allowing for the identification of biologically active library members within an intracellular environment where both the library and the target are present in their native conformations. Curve is…
PR Newswire
26/03/2024

STORM Therapeutics to Present Data on its First-in-Class METTL1 tRNA…

Oliver Rausch, Chief Scientific Officer at STORM Therapeutics, said: "We are looking forward to presenting these data on our first-in-class METTL1 inhibitor at the AACR Annual Meeting. As we continue to develop our pipeline of therapies inhibiting RNA modifying enzymes, we are pleased with the progress we are making with METTL1 and are looking forward to advancing this candidate towards clinical development." Oliver Rausch, Chief Scientific Officer at STORM Therapeutics, said: "We…
PR Newswire
26/03/2024

Asceneuron Joins Critical Path for Alzheimer's Disease Consortium

Ryan Schubert, Senior Vice President Research and Development at Asceneuron, said: "We are honored to be collaborating with the CPAD consortium alongside esteemed fellow members, all of whom are dedicated to accelerating drug development to improve patients' lives. CPAD has gathered high quality data and experts from industry, academia and regulatory agencies with a focus on bringing new treatment options to patients suffering with AD. We look forward to contributing to and impacting the…
PR Newswire
26/03/2024

Implantica completes Human Factors Validation Study for RefluxStop™ as part of…

The goal of the study is to demonstrate how surgeons at varying levels of surgical experience from academic, community, and private clinics in the US, carry out the RefluxStop™ procedure. The goal of the study is to demonstrate how surgeons at varying levels of surgical experience from academic, community, and private clinics in the US, carry out the RefluxStop™ procedure. In the next step of the study, an independent third party is evaluating the data collected during testing inChicago...
PR Newswire
26/03/2024

Intravacc announces positive data of first in human intranasal OMV based vaccine…

First in human phase I clinical study using OMV as an adjuvant for intranasal vaccinationAvacc 10 ®intranasal booster vaccine induces a mucosal response and no adverse eventsData will be presented at the World Vaccine Conference on April 3 rd2024 in Washington, DC BILTHOVEN, The Netherlands, March26, 2024(GLOBE NEWSWIRE) -- Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced positive clinical data of a...
Nasdaq GlobeNewswire
26/03/2024

Annual General Meeting 2024: Tecan proposes election of an additional member of…

Annual General Meeting 2024: Tecan proposes election of an additional member of the Board of Directors and various amendments to the Articles of IncorporationMonica Manotas proposed as a new member of the Board of DirectorsBoard of Directors will propose all current members for re-electionVarious amendments to the Articles of Incorporation proposed to adapt them to new circumstancesReport on non-financial matters submitted for approval for the first timeProposed dividend...
Nasdaq GlobeNewswire
26/03/2024

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES

PRESS RELEASE REGULATED INFORMATION 26 March 2024, 07:00 a.m. CETGhent, Belgium, 26 March 2024 – Sequana Medical NV(Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that in the context of the private placement of new shares that was announced and priced on 20 March 2024, with pricing announced on 21 March 2024, by means of a private placement through an...
Nasdaq GlobeNewswire
26/03/2024

ECHOSENS APPOINTS DR. VICTOR DE LÉDINGHEN AS CHIEF MEDICAL OFFICER

His dedication to advancing liver health is evident through his impressive contributions, including over 400 articles and 300 national and international congressional communications. His expertise in chronic liver diseases, particularly MASH, has been instrumental in shaping clinical practice worldwide. His dedication to advancing liver health is evident through his impressive contributions, including over 400 articles and 300 national and international congressional communications. His...
PR Newswire
26/03/2024

Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Saint-Herblain (France), March 26, 2024– Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate thethe safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika virus (ZIKV). There are currently no preventive vaccines or effective treatments available against ZIKV. As such, this mosquito-borne disease remains a public health threat...
Nasdaq GlobeNewswire
26/03/2024

CARBIOS joins Paris Good Fashion to accelerate textile circularity and…

CARBIOS joins Paris Good Fashion to accelerate textile circularity and contribute to more sustainable fashionClermont-Ferrand, France, Tuesday 26 March 2024 (06.45am CET) CARBIOS(Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, announces its membership to Paris Good Fashion, the association that unites over 100 French players in the sector - brands, designers and experts -...
Nasdaq GlobeNewswire
26/03/2024

Innocan Pharma paves its way to LPT-CBD Chemistry, Manufacturing and Controls…

To date, Innocan has focused on the development and characterization of LPT-CBD to achieve its long-term release and effectiveness. Innocan is now initiating the following essential development steps that are expected to move LPT-CBD to a pharmaceutical-grade product that must be qualified by the FDA for both the clinical and marketing phases: To date, Innocan has focused on the development and characterization of LPT-CBD to achieve its long-term release and effectiveness. Innocan is now...
PR Newswire
25/03/2024

OXURION announces its presence at the Paris SmallCap event on March 28, 2024.

OXURION announces its presence at the Paris SmallCap event on March 28, 2024. Leuven, BELGIUM - March 25, 2024 - 7:00 p.m, Oxurion NV (Euronext Brussels : OXUR), a Leuven-based biopharmaceutical company, is pleased to announce its participation in the SmallCap event, scheduled for March 28 in Paris.The event, organized in key cities such as Paris, London, Frankfurt and Amsterdam, serves as a platform for bringing together European issuers and a wider network of institutional investors...
Nasdaq GlobeNewswire
25/03/2024

ONWARD® Medical Publishes Closing of Accelerated Bookbuild Offering and Public…

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, March25, 2024(GLOBE NEWSWIRE)...
Nasdaq GlobeNewswire
25/03/2024
Altri  Comunicati